MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats

Brain Research

Volumn 862, Issue 1-2, 2000, Pages 111-119

  Liu, Yitao ^a   Belayev, Ludmila ^a   Zhao, Weizhao ^a   Busto, Raul ^a   Ginsberg, Myron D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Focal cerebral ischemia; Image analysis; MRZ 2 579; Neuroprotection

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; HUMAN; IMAGE ANALYSIS; MALE; MICRODIALYSIS; NEUROLOGICAL COMPLICATION; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT; TEMPERATURE;

ANIMALS; BRAIN EDEMA; BRAIN ISCHEMIA; CEREBRAL CORTEX; CYCLOPENTANES; EXCITATORY AMINO ACID AGONISTS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; N-METHYLASPARTATE; NEOSTRIATUM; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034678533     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02078-3     Document Type: Article

References (34)

1. Albers G.W. Potential therapeutic uses of N-methyl-D-aspartate antagonists in cerebral ischemia. Clin. Neuropharmacol. 13:1990;177-197.
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17:1986;472-476.
3. Belayev L., Alonso O.F., Busto R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 27:1996;1616-1622.
4. Benveniste H., Drejer J., Schousboe A., Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43:1984;1369-1374.
5. Buchan A.M. Do NMDA antagonists protect against cerebral ischemia: Are clinical trials warranted? Cerebrovasc. Brain Metab. Rev. 2:1990;1-26.
6. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
7. Choi D.W. Cerebral hypoxia: some new approaches and unanswered questions. J. Neurosci. 10:1990;2493-2501.
8. Cotman C.W., Iversen L.L. Excitatory amino acids in the brain - focus on NMDA receptors. Trends Neurosci. 10:1987;263-265.
9. Danysz W., Parsons A.G. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50:1998;597-664.
10. De Ryck M., Van Reempts J., Borgers M., Wauquier A., Janssen P.J. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 20:1989;1383-1390.
11. Ginsberg M.D. The new language of cerebral ischemia. Am. J. Neuroradiol. 18:1997;1435-1445.
12. Ginsberg M.D., Pulsinelli W.A. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke [editorial; comment]. Ann. Neurol. 36:1994;553-554.
13. Globus M.Y., Busto R., Dietrich W.D., Martinez E., Valdes I., Ginsberg M.D. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. J. Neurochem. 51:1988;1455-1464.
14. Hesselink M.B., De Boer B.G., Breimer D.D., Danysz W. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm. Res. 16:1999;637-642.
15. Hesselink M.B., Parsons C.G., Wollenburg C., Danysz W. Brain distribution of an uncompetitive NMDA receptor antagonist; comparison to its in vitro potency in electrophysiological studies. Naunyn Schmiedeberg's Arch Pharmacol. 360:1999;144-150.
16. B antagonists and partial agonists in rodent models of Parkinson's disease - comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 38:1999;109-119.
17. Koroshetz W.J., Moskowitz M.A. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17:1996;227-233.
18. Laing R.J., Jakubowski J., Laing R.W. Middle cerebral artery occlusion without craniectomy in rats: which method works best? Stroke. 24:1993;294-298.
19. Lee J.M., Zipfel G.J., Choi D.W. The changing landscape of ischaemic brain injury mechanisms. Nature. 399:1999;A7-14.
20. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:1997;S66-S69.
21. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330:1994;613-622.
22. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
23. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
24. Park C.K., Nehls D.G., Teasdale G.M., McCulloch J. Effect of the NMDA antagonist MK-801 on local cerebral blood flow in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab. 9:1989;617-622.
25. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 38:1999;85-108.
26. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11:1998;523-569.
27. Popik P., Mamczarz J., Fraczek M., Widla M., Hesselink M., Danysz W. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology. 37:1998;1033-1042.
28. Siegel S. Nonparametric Statistics for the Behavioral Sciences. 1956;McGraw-Hill, New York.
29. Sopala M., Danysz W. Comparison of chronic 2VO and transient MCAO in rats as potential models for studying neuroprotective compounds. Soc. Neurosci. Abstr. 24:1998;1954.
30. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10:1990;290-293.
31. B sites. Eur. J. Pharmacol. 347:1998;183-187.
32. Wesemann W., Sturm G., Funfgeld E.W. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J. Neural. Transm. Suppl. 1:1980;143-148.
33. Zea L., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.
34. Zhao W., Belayev L., Ginsberg M.D. Transient middle cerebral artery occlusion by intraluminal suture: II. Neurological deficits, and pixel-based correlation of histopathology with local blood flow and glucose utilization. J. Cereb. Blood Flow Metab. 17:1997;1281-1290.